Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.

The pharmacogenomics journal - 1 Oct 2014

Gassó P, Rodríguez N, Mas S, Pagerols M, Blázquez A, Plana M T, Torra M, Lázaro L, Lafuente A

Abstract excerpt

There is little known about pharmacogenetic of fluoxetine in children and adolescents. In this study, we evaluate, for the first time, the influence of CYP2D6, CYP2C9 and ABCB1 genotypes on the steady-state plasma concentrations of fluoxetine and its active metabolite (S)-norfluoxetine, and on the clinical improvement in children and adolescent patients receiving fluoxetine treatment. The assessment was performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP2D6

Share to Fluoxetine

Share to ABCB1 gene

Share to Genotype

Source

Identifiers

PMID: 24663076
DOI: 10.1038/tpj.2014.12

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.PMID 24663076Read ↗

Impact of Cytochrome P450 Genetic Variation on Patient-Reported Symptom Improvement and Side Effects Among Children and Adolescents Treated with Fluoxetine.Semantic proximity Read ↗

Fluoxetine pharmacogenetics in child and adult populations.Semantic proximity Read ↗

Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Semantic proximity Read ↗

Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity Read ↗

Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine.Semantic proximity Read ↗

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.Semantic proximity Read ↗

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.Semantic proximity Read ↗

Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.